Segment Reporting (Details) (USD $) In Millions	3 Months Ended				9 Months Ended
	Sep. 30, 2011		Sep. 30, 2010		Sep. 30, 2011	Sep. 30, 2010	Dec. 31, 2010
Reconciliation from Segment Totals to Consolidated [Line Items]
Product Sales	$ 1,018.4		$ 794.3		$ 2,901.0	$ 2,276.8
Royalties	62.8		76.5		199.8	254.5
Other Revenues	4.9		3.5		20.4	8.6
Revenues	1,086.1		874.3		3,121.2	2,539.9
Cost of Product Sales	166.5	[1]	112.7	[1]	434.7	333.7
Research and Development	201.5		197.9		556.3	475.9
Selling, General and Administrative	452.1	[1]	392.4	[1]	1,295.3	1,106.7
Loss/(gain) on sale of product rights	0.3		0		3.8	(4.1)
Reorganization Cost	5.0		9.7		18.0	23.3
Integration and Acquisition Cost	5.3		5.8		7.9	6.4
Total operating expenses	830.7		718.5		2,316.0	1,941.9
Operating Income (Loss)	255.4		155.8		805.2	598.0
Assets	6,065.6		5,101.6		6,065.6	5,101.6	5,387.6
Long-Lived Assets	921.2		821.8		921.2	821.8
Capital Expenditure on Long-Lived Assets	47.1		45.5		141.9	241.9
Depreciation and Amortization, by Report Line
Cost of Product Sales, Depreciation, Manufacturing Plant	10.8		8.5		29.0	26.9
Cost of Product Sales, Amortization, Favorable Manufacturing Contract	0.5		0.4		1.4	1.3
Research and Development Expense, Depreciation of Research and Development Asset	5.6		4.4		16.4	11.6
Selling, General and Administrative Expense, Depreciation and Amortization	63.1		90.0		165.5	191.3
Other Intangible Assets, Impairment Losses	16.0		42.7		16.0	42.7
Specialty Pharmaceuticals
Reconciliation from Segment Totals to Consolidated [Line Items]
Product Sales	658.0		553.0		1,948.8	1,645.7
Royalties	45.2		35.7		134.6	138.5
Other Revenues	3.6		1.5		15.9	2.7
Revenues	706.8		590.2		2,099.3	1,786.9
Cost of Product Sales	88.4		82.2		264.0	247.2
Research and Development	121.6		87.2		329.3	245.7
Selling, General and Administrative	273.8		284.8		833.8	771.0
Loss/(gain) on sale of product rights	0.3		0		3.8	(4.1)
Reorganization Cost	3.2		2.7		8.2	9.3
Integration and Acquisition Cost	1.7		5.8		(2.6)	6.4
Total operating expenses	489.0		462.7		1,436.5	1,275.5
Operating Income (Loss)	217.8		127.5		662.8	511.4
Assets	2,527.9		2,030.4		2,527.9	2,030.4
Long-Lived Assets	136.2		159.9		136.2	159.9
Capital Expenditure on Long-Lived Assets	12.8		3.1		35.9	8.2
Human Genetic Therapies
Reconciliation from Segment Totals to Consolidated [Line Items]
Product Sales	310.4		241.3		900.2	631.1
Royalties	0		0		0	0
Other Revenues	0.3		0.6		0.9	2.0
Revenues	310.7		241.9		901.1	633.1
Cost of Product Sales	59.9		29.0		152.2	85.0
Research and Development	76.5		110.0		223.5	229.3
Selling, General and Administrative	85.3		66.8		257.3	191.5
Loss/(gain) on sale of product rights	0		0		0	0
Reorganization Cost	0		0		0	0
Integration and Acquisition Cost	0		0		0	0
Total operating expenses	221.7		205.8		633.0	505.8
Operating Income (Loss)	89.0		36.1		268.1	127.3
Assets	1,835.2		1,706.5		1,835.2	1,706.5
Long-Lived Assets	703.7		615.9		703.7	615.9
Capital Expenditure on Long-Lived Assets	30.1		39.1		93.9	226.5
Regenerative Medicine
Reconciliation from Segment Totals to Consolidated [Line Items]
Product Sales	50.0		0		52.0	0
Royalties	0		0		0	0
Other Revenues	0		0		0	0
Revenues	50.0		0		52.0	0
Cost of Product Sales	18.2		0		18.5	0
Research and Development	3.4		0		3.5	0
Selling, General and Administrative	30.2		0		31.5	0
Loss/(gain) on sale of product rights	0		0		0	0
Reorganization Cost	0		0		0	0
Integration and Acquisition Cost	3.6		0		10.5	0
Total operating expenses	55.4		0		64.0	0
Operating Income (Loss)	(5.4)		0		(12.0)	0
Assets	972.7		0		972.7	0
Long-Lived Assets	20.2		0		20.2	0
Capital Expenditure on Long-Lived Assets	0.5		0		0.7	0
All Other Segment
Reconciliation from Segment Totals to Consolidated [Line Items]
Product Sales	0		0		0	0
Royalties	17.6		40.8		65.2	116.0
Other Revenues	1.0		1.4		3.6	3.9
Revenues	18.6		42.2		68.8	119.9
Cost of Product Sales			1.5		0	1.5
Research and Development	0		0.7			0.9
Selling, General and Administrative	62.8		40.8		172.7	144.2
Loss/(gain) on sale of product rights	0		0		0	0
Reorganization Cost	1.8		7.0		9.8	14.0
Integration and Acquisition Cost			0		0	0
Total operating expenses	64.6		50.0		182.5	160.6
Operating Income (Loss)	(46.0)		(7.8)		(113.7)	(40.7)
Assets	729.8		1,364.7		729.8	1,364.7
Long-Lived Assets	61.1		46.0		61.1	46.0
Capital Expenditure on Long-Lived Assets	$ 3.7		$ 3.3		$ 11.4	$ 7.2

[1] Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.5 million for the three months to September 30, 2011 (2010: $0.4 million) and $1.4 million for the nine months to September 30, 2011 (2010: $1.3 million). Research and development costs include impairment charges of $16.0 million for the three and nine months to September 30, 2011 (2010: $nil). Selling, general and administrative costs includes amortization and impairment charges of intangible assets relating to intellectual property rights acquired of $46.4 million for the three months to September 30, 2011 (2010: $73.9 million) and $119.1 million for the nine months to September 30, 2011 (2010: $142.3 million).